advertisement

Topcon

Lu DW 8

Showing records 1 to 8 | Display all abstracts from Lu DW

70846 Silibinin Inhibits Platelet-Derived Growth Factor-Driven Cell Proliferation via Downregulation of N-Glycosylation in Human Tenon's Fibroblasts in a Proteasome-Dependent Manner
Chen YH
PLoS ONE 2016; 11: e0168765
70222 Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
Chen YY; Wang TH
BMC Ophthalmology 2016; 16: 162
70846 Silibinin Inhibits Platelet-Derived Growth Factor-Driven Cell Proliferation via Downregulation of N-Glycosylation in Human Tenon's Fibroblasts in a Proteasome-Dependent Manner
Chen CL
PLoS ONE 2016; 11: e0168765
70222 Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
Liu C
BMC Ophthalmology 2016; 16: 162
70846 Silibinin Inhibits Platelet-Derived Growth Factor-Driven Cell Proliferation via Downregulation of N-Glycosylation in Human Tenon's Fibroblasts in a Proteasome-Dependent Manner
Lu DW; Liang CM
PLoS ONE 2016; 11: e0168765
70222 Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
Wu KY; Chiu SL
BMC Ophthalmology 2016; 16: 162
70846 Silibinin Inhibits Platelet-Derived Growth Factor-Driven Cell Proliferation via Downregulation of N-Glycosylation in Human Tenon's Fibroblasts in a Proteasome-Dependent Manner
Tai MC; Chen JT
PLoS ONE 2016; 11: e0168765
70222 Tolerability and efficacy of bimatoprost 0.01 % in patients with open-angle glaucoma or ocular hypertension evaluated in the Taiwanese clinical setting: the Asia Pacific Patterns from Early Access of Lumigan 0.01 % (APPEAL Taiwan) study
Simonyi S; Lu DW
BMC Ophthalmology 2016; 16: 162

Issue 18-2

Change Issue


advertisement

Oculus